Cirrhosis and liver cancer are among the leading causes of death in Vietnam, with some of the highest incidence rates in the Asia-Pacific region. Early diagnosis plays a crucial role in treatment and improving the quality of life for patients. In a collective effort to address this challenge, M2BPGi – a blood biomarker test – promises a breakthrough in the early diagnosis of liver cancer and cirrhosis.

